Volker Herrmann
Chief Executive Officer at Sonata Therapeutics, Inc.
Profile
Volker Herrmann is currently the CEO Partner at Flagship Pioneering and President, Chief Executive Officer & Director at Sonata Therapeutics, Inc. He is also the Chief Commercial Officer at Viamet Pharmaceuticals, Inc. and President at Inzen Therapeutics, Inc. Previously, he was the President & Chief Operating Officer at SQZ Biotechnologies Co. He holds a doctorate from the University of Freiburg and an MBA from the University of San Diego School of Business Administration.
Volker Herrmann active positions
Companies | Position | Start |
---|---|---|
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Corporate Officer/Principal | 2015-10-31 |
Inzen Therapeutics, Inc.
Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | President | - |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2020-07-31 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | Chief Executive Officer | - |
Former positions of Volker Herrmann
Companies | Position | End |
---|---|---|
SQZ BIOTECHNOLOGIES COMPANY | President | 2020-05-31 |
Training of Volker Herrmann
University of San Diego School of Business Administration | Masters Business Admin |
University of Freiburg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
Private companies | 4 |
---|---|
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Inzen Therapeutics, Inc.
Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | Health Technology |
- Stock Market
- Insiders
- Volker Herrmann